Boston Scientific Business Combination, Contingent Consideration, Liability, Current increased by 6.8% to $78.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 25.8%, from $62.00M to $78.00M. Over 4 years (FY 2020 to FY 2024), Business Combination, Contingent Consideration, Liability, Current shows an upward trend with a 24.8% CAGR.
other_business_combination_contingent_consideration_liab_d9be34| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $258.00M | $253.00M | $289.00M | $393.00M | $133.00M | $87.00M | $74.00M | $83.00M | $97.00M | $109.00M | $304.00M | $182.00M | $175.00M | $62.00M | $63.00M | $114.00M | $73.00M | $78.00M |
| QoQ Change | — | -1.9% | +14.2% | +36.0% | -66.2% | -34.6% | -14.9% | +12.2% | +16.9% | +12.4% | +178.9% | -40.1% | -3.8% | -64.6% | +1.6% | +81.0% | -36.0% | +6.8% |
| YoY Change | — | — | — | — | -48.4% | -65.6% | -74.4% | -78.9% | -27.1% | +25.3% | +310.8% | +119.3% | +80.4% | -43.1% | -79.3% | -37.4% | -58.3% | +25.8% |